Share
17 Posts.
lightbulb Created with Sketch. 9
clock Created with Sketch. 23/04/24
04:44
Share
Originally posted by Silverchair:
↑
Good appointments. Dr Rodenburger helped achieve the FDA approval for Clinuvel in the past with EPP, also knows Vitiligo and obtaining FDA approval in this blockbuster should be easier as the drug is already approved with a long track record of safety and showing efficacy would appear to be quite simple relatively. Approval for a new indication easier than a whole new drug application, with safety well established, so hopefully this becomes the standard of care in just a handful of years.
Expand
Due to the limited number of outstanding shares, the volatility of CUV is brutal. As you rightly pointed out, a large buyer was sufficient to drive the stock temporarily higher. However, the flip side is that a single large (short) seller is enough to send the stock plummeting. Retail investors don't move the stock price. Most of them just hold. Shorty has managed to create distrust, or rather, exploit the distrust in CUV. The failure to meet many targets has led to this. It's possible that massive investment will only resume when it's black and white that the FDA has granted approval for vitiligo.
(20min delay)